How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

334,466 results for

cardio*

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Promoting patient utilization of outpatient cardiac rehabilitation: A joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement Full Text available with Trip Pro

them to complete programs. Previous article in issue Next article in issue Keywords Coronary artery disease Secondary prevention Health services accessibility Disease management Cardiac rehabilitation Recommended articles Citing articles (0) Endorsed by: American Society for Preventive Cardiology, Association Francophone de Cardiologie Préventive, Australian Cardiovascular Health and Rehabilitation Association, Brazilian Association of Cardiorespiratory and Intensive Care Physiotherapy, Brazilian (...) Group of Cardiopulmonary and Metabolic Rehabilitation, British Association for Cardiovascular Prevention and Rehabilitation, Canadian Association of Cardiovascular Prevention and Rehabilitation, Canadian Cardiovascular Society, Canadian Council of Cardiovascular Nurses, Cardiac Health Foundation of Canada, Cardiac Society Brunei Darussalam, Indonesian Heart Association, International Council of Cardiovascular Prevention and Rehabilitation, International Society of Physical and Rehabilitation

2020 CPG Infobase

2. Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death

Subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death Subcutaneous implantable cardio Subcutaneous implantable cardiov verter erter defibrillator insertion for pre defibrillator insertion for prev venting sudden enting sudden cardiac death cardiac death Interventional procedures guidance Published: 20 December 2017 nice.org.uk/guidance/ipg603 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful (...) details about all patients having subcutaneous implantable cardioverter defibrillator insertion for preventing sudden cardiac death onto a register by submitting data to the National Audit of Cardiac Rhythm Management database at the UK National Institute for Cardiovascular Outcomes Research (NICOR), and should review local clinical outcomes. 1.3 The procedure should only be done by clinicians with specific training on inserting the device. 2 2 Indications and current treatments Indications

2018 National Institute for Health and Clinical Excellence - Interventional Procedures

3. Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence

Emirates" OR "U.S. Virgin Islands") #6 #1 AND #2 AND #3 AND #4 AND #5 LIMIT-TO ( LANGUAGE , "English" ) #7 TITLE-ABS-KEY("cardiovascular disease" or "coronary heart disease" or "ischemic" or "coronary artery disease" or "heart disease" or "heart attack" or "stroke" or "myocardial infarction" or "heart failure" or "cardiovascular disease” or "cerebrovascular disease" or "cerebrovascular event" or "angina" or "coronary disease" or "coronary artery disease" or "ischemia" OR cardiomyopathy OR “heart (...) Cardiovascular Disease: Tailored Pharmacy-based Interventions to Improve Medication Adherence Cardiovascular Disease: Medication Adherence | The Community Guide Welcome to The Community Guide! Let us know what you think of the website by completing this . Open Navigation or Search form Search Search The Community Guide You are here » Systematic Review Topic Recommended (strong evidence) April 2019 Audience Adults Older Adults Setting Clinical/Health Systems Community Strategy Case Management

2020 Community Preventive Services Task Force

4. Cardiovascular disease prevention: applying All Our Health

Cardiovascular disease prevention: applying All Our Health Cardiovascular disease prevention: applying All Our Health - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance Cardiovascular disease prevention: applying All Our Health Evidence and guidance to help healthcare (...) professionals to prevent heart attacks, strokes and dementia and to improve cardiovascular health. Published 9 January 2019 Last updated 16 December 2019 — From: Documents HTML Details This resource helps: front-line health professionals team leaders or managers senior or strategic leaders to prevent ill health and promote wellbeing as part of their everyday practice. We also recommend important actions that managers and staff holding strategic roles can take. View the full range of topics. Published 9

2020 Public Health England

5. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...)  |   |  Spotlight In the January issue of Prescrire International - Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications FREE DOWNLOAD In the "Reviews" section this month: what is dapagliflozin's harm-benefit balance in type 2 diabetes, in light of the results of a recent randomised, double-blind trial studying the drug's effect on cardiovascular outcomes? Full text available for free download. Summary A randomised, double-blind trial of dapagliflozin

2020 Prescrire

6. Remote ECG interpretation consultancy services for cardiovascular disease

cardiologist, Raigmore Hospital, NHS Highland, member of the British Cardiovascular Intervention Society. No relevant conflicts of interest. Mr Charlie Bloe, clinical ward manager, NHS Highland, member of SHARP (Scottish Heart and Arterial disease Risk Prevention). Mr Bloe is the clinical lead and managing director for a private healthcare education company and provides regular tuition to healthcare professionals on electrocardiogram (ECG) interpretation. Dr Richard Schilling, professor of cardiology (...) Remote ECG interpretation consultancy services for cardiovascular disease Remote ECG interpretation consultancy services Remote ECG interpretation consultancy services for cardio for cardiovascular disease vascular disease Medtech innovation briefing Published: 27 July 2018 nice.org.uk/guidance/mib152 pathways Summary Summary The technologies technologies described in this briefing are remote electrocardiogram (ECG) interpretation consultancy services. They are used for assisting in diagnosing

2018 National Institute for Health and Clinical Excellence - Advice

7. Exercise-based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator. Full Text available with Trip Pro

Exercise-based cardiac rehabilitation for adult patients with an implantable cardioverter defibrillator. An effective way of preventing sudden cardiac death is the use of an implantable cardioverter defibrillator (ICD). In spite of the potential mortality benefits of receiving an ICD device, psychological problems experienced by patients after receiving an ICD may negatively impact their health-related quality of life, and lead to increased readmission to hospital and healthcare needs, loss

2019 Cochrane

8. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. (Abstract)

Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Atrial fibrillation is the most frequent sustained arrhythmia. Atrial fibrillation often recurs after restoration of normal sinus rhythm. Antiarrhythmic drugs have been widely used to prevent recurrence. This is an update of a review previously published in 2006, 2012 and 2015.To determine the effects of long-term treatment with antiarrhythmic drugs on death, stroke, drug adverse effects and recurrence

2019 Cochrane

9. Promoting patient utilization of outpatient cardiac rehabilitation: A joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement

Promoting patient utilization of outpatient cardiac rehabilitation: A joint International Council and Canadian Association of Cardiovascular Prevention and Rehabilitation position statement ClinicalKey

2019 CPG Infobase

10. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. Full Text available with Trip Pro

Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. The Seven Countries study in the 1960s showed that populations in the Mediterranean region experienced lower coronary heart disease (CHD) mortality probably as a result of different dietary patterns. Later observational studies have confirmed the benefits of adherence to a Mediterranean dietary pattern on cardiovascular disease (CVD) risk factors but clinical trial evidence is more limited.To determine

2019 Cochrane

11. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. (Abstract)

Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary oedema. Non-invasive positive pressure ventilation (NPPV) has been used to treat respiratory distress due to acute cardiogenic pulmonary oedema (ACPE). We performed a systematic review and meta-analysis update on NPPV for adults presenting with ACPE.To evaluate the safety and effectiveness of NPPV compared to standard medical care (SMC) for adults with ACPE. The primary outcome was hospital mortality

2019 Cochrane

12. Epidural analgesia for adults undergoing cardiac surgery with or without cardiopulmonary bypass. (Abstract)

Epidural analgesia for adults undergoing cardiac surgery with or without cardiopulmonary bypass. General anaesthesia combined with epidural analgesia may have a beneficial effect on clinical outcomes. However, use of epidural analgesia for cardiac surgery is controversial due to a theoretical increased risk of epidural haematoma associated with systemic heparinization. This review was published in 2013, and it was updated in 2019.To determine the impact of perioperative epidural analgesia (...) in adults undergoing cardiac surgery, with or without cardiopulmonary bypass, on perioperative mortality and cardiac, pulmonary, or neurological morbidity.We searched CENTRAL, MEDLINE, and Embase in November 2018, and two trial registers up to February 2019, together with references and relevant conference abstracts.We included all randomized controlled trials (RCTs) including adults undergoing any type of cardiac surgery under general anaesthesia and comparing epidural analgesia versus another modality

2019 Cochrane

13. The use of statins in the primary prevention of cardiovascular disease: an online tool for shared-decision making

OF ABBREVIATIONS ABBREVIATION DEFINITION CPG Committee for Practice Guidelines CVD Cardiovascular Disease DA Decision Aid ESC – EAS European Society of Cardiology – European Atherosclerosis Society EuroSCORE European Systemic Coronary Risk Estimation HDL High Density Lipoprotein IDL Intermediate Density Lipoprotein LDL Low Density Lipoprotein NIHDI National Institute for Health and Disability Insurance (RIZIV – INAMI) PROCAM Prospective Cardiovascular Münster RCT Randomized Clinical Trial SCORE Systematic (...) properties. The relationship between HDL cholesterol and cardiovascular risk is complex. HDL is probably not directly associated with CVD, but may be a risk factor of dyslipidemia: the increase of HDL cholesterol observed with a better lifestyle represent a marker of reduced CVD risk. 7, 8 The ESC/EAS (European Society of Cardiology and European Atherosclerosis Society) guidelines for the management of dyslipidaemias recommend initiation of prevention of CVD events with drug therapy in individuals

2020 Belgian Health Care Knowledge Centre

14. Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease

Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Cardiovascular Benefits and Harms of Step Therapy in the Treatment of Type 2 Diabetes in Adults with and without Atherosclerotic Cardiovascular Disease Kaiser Permanente Research Affiliates Evidence-based Practice Center Corinne Evans, MPP; Nicholas Emptage, MAE; Megan Rushkin, MPH; and Jennifer S. Lin, MD, MCR Summary Question 1. In persons (...) with type 2 diabetes with or without known atherosclerotic cardiovascular disease (ASCVD) who cannot attain adequate glucose control with metformin, what is the benefit of GLP-1 agonists or SGLT-2 inhibitors on cardiovascular morbidity and mortality? • Evidence of benefit in persons with known ASCVD on cardiovascular disease (CVD) outcomes, CVD mortality and all-cause mortality (ACM) o Based on limited evidence in persons without ASCVD, no evidence of benefit on CVD outcomes • Presumed class effect

2019 Kaiser Permanente National Guideline Program

15. Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer

Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer 1 Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer Interim Guidance from the Kaiser Permanente National Integrated Cardiovascular Health (ICVH) Work Group October 5, 2018 Three randomized clinical trials (ARRIVE 1 , ASCEND 2 , and ASPREE 3 ) recently published results on aspirin use in patients without known Atherosclerotic Cardiovascular Disease (ASCVD). The studies looked at benefits including (...) cardiovascular event prevention, and risks including serious bleeding events. Overall the studies suggest that aspirin lacks net benefit (total benefits minus total harms) beyond age 70, and there is low net benefit in younger adults. USPSTF 2016 aspirin recommendations point to highest net benefit for aspirin in adults age 50-59 (lower bleeding risk than older patients) with 10-year ASCVD risk* >10%. The National Kaiser Permanente Aspirin recommendations will be formally updated following a comprehensive

2019 Kaiser Permanente National Guideline Program

16. Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases developed in collaboration with the EASD Full Text available with Trip Pro

in the 2019 Guidelines? Table 3 What is new in the 2019 Guidelines? AF = atrial fibrillation; BMS = bare-metal stent; BP = blood pressure; CABG = coronary artery bypass graft; CAD = coronary artery disease; CV = cardiovascular; CVD = cardiovascular disease; DBP = diastolic blood pressure; DES = drug-eluting stent; DM = diabetes mellitus; EACTS = European Association for Cardio-Thoracic Surgery; ESC = European Society of Cardiology; LAD = left anterior descending coronary artery; LDL-C = low-density (...) = cardiovascular disease; DBP = diastolic blood pressure; DES = drug-eluting stent; DM = diabetes mellitus; EACTS = European Association for Cardio-Thoracic Surgery; ESC = European Society of Cardiology; LAD = left anterior descending coronary artery; LDL-C = low-density lipoprotein cholesterol; NOAC = non-vitamin K antagonist oral anticoagulant; PCI = percutaneous coronary intervention; SBP = systolic blood pressure; SYNTAX = Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery

2019 European Society of Cardiology

17. Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects

Erenumab (Aimovig) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects Prescrire IN ENGLISH - Spotlight ''Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects '', 1 September 2019 {1} {1} {1} | | Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Erenumab (Aimovig°) for the prevention of migraine attacks: decrease in the frequency of attacks in some patients, but uncertainty over cardiovascular effects FEATURED REVIEW Erenumab (Aimovig°) is a monoclonal antibody that has been authorised in the European Union for the prevention of migraine attacks in patients who experience attacks on more than 4 days a month. Prescrire's editorial staff have weighed

2019 Prescrire

18. PET-CT for Cardiology: A Rapid Qualitative Evidence Synthesis of Patients’ and Caregivers’ Perspectives and Experiences

PET-CT for Cardiology: A Rapid Qualitative Evidence Synthesis of Patients’ and Caregivers’ Perspectives and Experiences PET-CT for Cardiology: A Rapid Qualitative Evidence Synthesis of Patients’ and Caregivers’ Perspectives and Experiences | CADTH.ca Find the information you need PET-CT for Cardiology: A Rapid Qualitative Evidence Synthesis of Patients’ and Caregivers’ Perspectives and Experiences PET-CT for Cardiology: A Rapid Qualitative Evidence Synthesis of Patients’ and Caregivers

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

19. Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines

Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Acetylsalicylic Acid for Primary Prevention of Cardiovascular Events: Clinical Effectiveness and Guidelines Last updated: August 19 (...) , 2019 Project Number: RB1368-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness for the use of acetylsalicylic acid in primary prevention of cardiovascular disease? What are the evidence-based guidelines for the use of acetylsalicylic acid in primary prevention of cardiovascular disease? Key Message Twenty-two systematic reviews and meta-analyses, eight randomized controlled trials, and eleven non-randomized studies

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

20. Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha) and alirocumab (Praluent)

Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha) and alirocumab (Praluent) Prescrire IN ENGLISH - Spotlight ''Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°)'', 1 October 2019 {1} {1} {1} | | > > > Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°) Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |  (...)  |   |   |   |   |   |   |  Spotlight Secondary cardiovascular prevention: dubious benefits of evolocumab (Repatha°) and alirocumab (Praluent°) In patients who have already had a cardiovascular event, the addition of evolocumab or alirocumab to a statin does not reduce mortality but does expose to adverse effects, although these are not well known. In patients who have had a previous cardiovascular event (myocardial infarction, stroke

2019 Prescrire

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>